Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03311308 · ClinicalTrials.gov registry record · Phase 1
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
A Phase 1 study of Advanced Melanoma, sponsored by Yana Najjar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03311308 is a Phase 1 study of Advanced Melanoma that is actively recruiting participants, run by Yana Najjar. The registered enrollment target is 30 participants, below the 170-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03311308, a Phase 1 study of Advanced Melanoma, is actively recruiting participants, sponsored by Yana Najjar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Pembrolizumab Injection [Keytruda]
Study Locations (1)
Pennsylvania
- Univ of Pittsburgh Medical Center Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03311308
The ClinicalTrials.gov registry entry for NCT03311308 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (82% lower). The listed sponsor is Yana Najjar, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT03311308 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03311308 about?
NCT03311308 is a clinical study titled "A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma". The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
What is the current status of trial NCT03311308?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-02-07. Estimated completion is 2029-12.
What conditions does trial NCT03311308 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT03311308?
The interventions under investigation include: Metformin (DRUG), Pembrolizumab Injection [Keytruda] (DRUG).
Who is sponsoring clinical trial NCT03311308?
This trial is sponsored by Yana Najjar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03311308 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Naltrexone and Propranolol Combined With Immunotherapy
RECRUITING · Phase 1
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
RECRUITING · Phase 1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.